Molecular Defects in the Ehlers-Danlos Syndrome  by Pinnell, Sheldon R.
0022-202X/82/79o:l-090s$02.00/0 
THE .JOURNAL OF INVESTIGATIVE DERMATOLOGY, 79:908-92s, 1982 
Copyright © 1!J82 hy The Williams & Wilkins Co. 
V "I. 7�). Supplement I 
Printed in U.S.A. 
Molecular Defects in the Ehlers-Danlos Syndrome 
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Several abnormalities in collagen biosynthesis have 
been described in patients with Ehlers-Danlos syndrome. 
Examples of collagen structural mutations as well as 
post-translational enzymatic defects have been detected. 
Patients with hydroxylysine-deficient collagen disease 
(Ehlers-Danlos type VI) have diminished lysyl hydroxy­
lase activity. One mutant enzyme has been characterized 
which is thermally labile and had an altered affinity for 
ascorbate. Another mutant enzyme had a normal re­
quirement for cofactors but activity was diminished. 
Type VII Ehlers-Danlos syndrome is associated with 
altered processing of procollagen to collagen. Most often 
the disorder is associated with deficient procollagen 
aminoprotease activity. One patient appears to repre­
sent a structural mutation of pro 0'2 (I) resulting in in­
complete cleavage of the amino terminal propeptide. One 
family with x-linked Ehlers-Danlos syndrome (type V) 
has been described with altered lysyl oxidase activity. 
Other patients with this disorder have had normal lysyl 
oxidase activity. The ecchymotic form of Ehlers-Danlos 
syndrome (type IV) has defective type III collagen syn­
thesis. Patients have been described with absent synthe­
sis, diminished synthesis and diminished secretion. 
The Ehlers-Danlos syndrome is a striking clinical syndrome 
with rubber-like skin, hypermobile joints, a tendency to bruise 
easily, and poor wound healing [1). In general most forms of 
the disorder are compatible with normal longevity; a striking 
exception is the ecchymotic form of Ehlers-Danlos syndrome 
in which premature demise occurs regularly from arterial or 
intestinal rupture. In 1972, the fIrst human molecular disorder 
of collagen, hydroxylysine-defIcient collagen disease, was de­
scribed in 2 sisters with Ehlers-Danlos syndrome [2). Since then 
several ultrastructural and biochemical collagen defects have 
been described in the Ehlers-Danlos syndrome (Table). This 
manuscript will focus on 4 types of Ehlers-Danlos syndrome in 
which biochemical collagen defects are best understood: types 
VI, VII, V, and IV. The range of defects is representative of the 
complex nature of collagen biosynthesis. These appear to in­
clude structural and regulatory collagen genomic alterations as 
well as intracellular and extracellular post-translation enzy­
matic defects. 
TYPE VI EHLERS-DANLOS SYNDROME: 
HYDROXYLYSINE-DEFICIENT COLLAGEN DISEASE 
In 1972, Pinnell et al described 2 sisters with type VI Ehlers­
Danlos syndrome who had marked hyperextensibility of skin 
and joints, severe scoliosis, and marfanoid features [2). Levels 
of hydroxylysine in skin collagen were found to be less than one 
per molecule of collagen and levels of hydroxylysine-derived 
cross-links were marked diminished [3]. The disorder is due to 
deficient lysyl hydroxylase activity [4] and is inherited as an 
autosomal recessive. Heterozygotes have intermediate activities 
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of lysyl hydroxylase. Two mutant enzymes have been charac­
terized. One has an altered affInity for ascorbate and is ther­
mally labile [5]. This apparently represents a structural muta­
tion of the enzyme. The other enzyme was kinetically normal 
but the activity was markedly diminished [6). This may repre­
sent a structural or regulatory mutation. 
The relative hydroxylation of tissue collagens has been vari­
able in this disorder [2, 7]. Although skin was markedly defIcient 
in hydroxylysine, bone was less defIcient and cartilage was 
normally hydroxylated. The explanation for this variability is 
unknown although enzymatic polymorphism has not been ex­
cluded. Indeed evidence for isozymes has been reported [8]. 
When cell lysates from a lysyl hydroxylase defIcient cell strain 
were tested against substrates for types I and IV collagen, 
preferential activity was demonstrated against type IV collagen. 
In one study an almost normal hydroxylysine content in skin 
collagen was described in association with lysyl hydroxylase 
defIciency [9] . Subsequent analysis of these skin fIbroblasts 
however has revealed normallysyl hydroxylase activity (Murad 
S, Pinnell SR: unpublished observations and Steinmann B: 
personal communcation). 
The hydroxylysine content of complement component Clq 
was slightly low [10] or normal [ll] and functional activity was 
unimpaired. 
Therapy with large doses of ascorbate was effective in one 
patient with this disorder [12]. He was able to boost his urinary 
excretion of hydroxylysine although hydroxyproline excretion 
was coordinately increased. The effect appears to be due to an 
overall stimulation of collagen synthesis by ascorbate [1.3] 
rather than specific stimulation of lysyl hydroxylase activity. 
Kinetic studies of his mutant enzyme failed to detect any 
alteration in affinity for ascorbate [6). 
TYPE VII EHLERS-DANLOS SYNDROME: 
90s 
ARTHROCHALASIS MULTIPLEX CONGENITA 
In 1973, Lichtenstein et al reported studies on :1 type VII 
Ehlers-Danlos patients with a defect in conversion of procolla­
gen to collagen [14]. These patients had short stature, hyper­
extensible joints, and bilateral hip dislocation. Analysis of col­
lagen extracted from their skin revealed elongated oc] (I) and 
OC2 (I) chains resulting from inefficient conversion of type I 
procollagen. Their cultured skin fibroblasts had deficient pro­
collagen aminoprotease activity. Uncleaved aminoterminal pro­
peptides apparently interfere with fibrillogenesis and intermo­
lecular crosslinking resulting in the fragile connective tissue. 
This disorder, inherited as an autosomal recessive, is bio­
chemically similar to dermatosparaxis found in sheep [15] and 
cattle [16]. The striking skin fragility characteristic of derma­
tosparaxis however, is absent in the Ehlers-Danlos patients. 
The reason for this difference is not understood. 
Recently another patient with type VII Ehlers-Danlos syn­
drome has been described with inefficient conversion of procol­
lagen to collagen [17]. This patient has normal levels of procol­
lagen aminoprotease. Conversion of pro collagen appears to be 
impeded by a structural mutation in her pro OC2 (1) near the 
protease cleavage site. Pro oc] (I) is normally converted but the 
aminopropeptide of pro OC2 (I) remains uncleaved apparently 
resulting in similar difficulties in fibrillogenesis found in other 
patients with this form of Ehlers-Danlos syndrome. This patient 
has, in addition to an abnormal pro OC2 (I), an equal complement 
of normal pro (\'2 (I). She apparently represents a new structural 
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Ultrastructural and biochemical collagen defects in Ehlers-Danlos 
syndrome 
Type Major clinical Ultrastructural Biochemical de-features defect feet 
I (Gravis) Marked joint and Variable collagen Unknown 
skin hyperexten- fibril diameter 
sibility. Fragile [29-31] 
skin, poor 
wound healing 
and easy bruisa-
bility. 
II (Mitis) Small joint hyper- Variable collagen Unknown 
mobility fibril diameter 
[30,31] 
III (Benign hy- Large joint hyper- Small collagen fi- Unknown 
perrnobile) mobility bril diameter 
[30] 
IV (Ecchy- Marked bruisabil- Small collagen fi- Diminished 
motic) ity. arterial and bril diameter [25-28] or ab-
intestinal rup- [27] sent [23] type 
ture Dilated endoplas- III collagen syn-
mic reticulum thesis. Some pa-
[26,27] tients may have 
secretion defect 
[26,27] 
V (X-linked) Moderate joint hy· Variable collagen Some patients 
permobility. fibril diameter may have lysyl 
Heart valve pro- [30,31] oxidase defi-
lapse. ciency [17J 
VI (Hydroxy- Marked joint hy- None detected [2] Lysyl hydroxylase 
lysine-defi- permobility. deficiency [4-6] 
cient) Kyphoscoliosis 
Ocular fragility 
V II (Arthro- Marked joint hy- Not determined Procollagen ami-
chalasis mul- permobility noprotease defi-
tiplex con- Dislocated hips ciency [14,17] 
genital One patient with 
structural defect 
VIII (Peri- Periodontitis Not determined 
in prop(I) [171 
Unknown 
odontitis) Skin fragility 
VIII (Mental HerniaR Not determined Unknown 
retardation) Mental retardation 
mutation resulting in one normal and one mutant allele for pro 
£\:2 (I). 
TYPE V EHLERS-DANLOS SYNDROME: X-LINKED 
In 1975, Di Ferrante et al reported studies on a patient with 
type V Ehlers-Danlos syndrome whose 2 male cousins were 
similarly affected [18]. The mothers were sisters, thus the 
disease was probably inherited as an X-linked recessive. Studies 
of skin fibroblasts in culture revealed increased collagen solu­
bility as well as deficient lysyl oxidase activity. It should be 
noted that the lysyl oxidase activity in the control cell strain 
was minimal and the study failed to take into account the 
limited solubility of lysyl oxidase [19] and the striking effect of 
cellular density on lysyl oxidase activity [20]. Later Siegel, 
Black, and Bailey examined other patients with X-linked Eh­
lers-Danlos and found normal levels in skin of lysyl oxidase and 
intermolecular collagen crosslinks [21]. Subsequently Byers et 
aI described a family with X-linked cutis laxa associated with 
lysyl oxidase deficiency apparently related to abnormal copper 
metabolism [22]. These patients had hyperextensible joints, a 
clinical feature more characteristic of Ehlers-Danlos syndrome 
than cutis laxa. 
TYPE IV EHLERS-DANLOS SYNDROME 
Clinical characteristics are different from other forms of 
Ehlers-Danlos syndrome in type IV Ehlers-Danlos syndrome. 
Bruising is prominent; skin is thin, transparent and fragile; 
tissues are not distensible; and healing may occur with hyper­
trophic scarring or keloids. Rupture of large arteries or perfo­
ration of gastrointestinal structures are common and life­
threatening. Although autosomal dominant and autosomal re­
cessive forms of this disorder occur, biochemical studies have 
been carried out only on the autosomal recessive form. 
In 1975, Pope et al reported a patient with type IV Ehlers-
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Danlos syndrome with absent type III collagen synthesis [23]. 
Skin, aorta, gut, bone, and tendon were obtained shortly after 
death. Cyanogen bromide cleavage of these tissues revealed 
absence of peptides characteristic of type III collagen. Skin 
fibroblasts in culture failed to synthesize any detectable type 
III procollagen. In addition, characteristic cellular staining was 
absent in cultured skin fibroblasts from the patient using anti­
sera specific for type III collagen and procollagen [24]. This 
patient may have had a gene deletion for type III procollagen. 
Subsequent studies of fibroblasts from patients with type IV 
Ehlers-Danlos syndrome have revealed diminished but not 
absent levels of type III collagen synthesis [25, 26]. They may 
represent structural or regulatory mutations. Electron micro­
scopic studies have revealed small collagen fiber diametrers [26, 
27]. In 2 patients distended endoplasmic reticulum has been 
demonstrated in skin [28] and lung [26] fibroblasts. These 
fibroblasts demonstrated diminished total collagen synthesis 
and markedly deficient type III collagen synthesis [26, 28]. 
They may represent mutations which interfere with cellular 
secretion. 
The Ehlers-Danlos phenotype is obviously associated with 
defective collagen structure. The variety of structural defects 
and abnormalities in post-translational modifications repre­
sented by the different forms of Ehlers-Danlos syndrome are 
characteristic of the complicated nature of collagen biosyn­
thesis. 
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